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Disseminated non-segmental vitiligo with halo nevi and grey hair
Vignesh Ramachandran MD, Katelyn M. Kim MD, and Lisa B. Zhang MD
Henry Ford Health System, Detroit, Michigan
Introduction

Clinical Photographs

Halo nevi (HN, also known as Sutton's nevi) are typically an
acquired melanocytic nevus (junctional, dermal, or
compound) surrounded by a circular white depigmented
region. Congenital nevi may also present as HN. Irrespective
of onset, HN may naturally resolve during their clinical
course.1 They are considered benign and affect 1% of
Caucasian individuals, appearing in childhood or early
2
adulthood.
HN may be associated with non-segmental
vitiligo. Herein, we report a rare triad of rapid-onset HN,
non-segmental vitiligo and premature hair graying (PHG).

Case History
A healthy 20-year-old male presented to our dermatology
clinic with a 5-month history of asymptomatic depigmented
lesions on his trunk and diffuse graying of his hair. He initially
noted an acute onset of these asymptomatic lesions slowly
enlarging around nevi on his chest and abdomen. Three
months later, he developed similar appearing and slowly
enlarging areas of involvement disassociated from nevi on his
back and progressive graying of his scalp hair. The skin of the
perifollicular scalp was not affected. He denied new or
changing moles and reported no associated symptoms.
Personal and family histories were negative for vitiligo,
autoimmune conditions, and skin cancer.

Examination
• He had numerous, isolated depigmented macules and
patches on the trunk and back, with some surrounding
symmetric, evenly pigmented, well-demarcated 3-6-mm
brown-black macules (Figure 1).
• The left upper inner arm had isolated 2 small depigmented
patches and the right inner thigh had 1 hypopigmented
patch.
• He had diffuse graying of his scalp hair without apparent
nevi of the scalp (Figure 2).
• Overall, he had approximately 5% body surface area
involvement.
• Wood’s lamp examination revealed lesion enhancement and
depigmentation of these various lesions.

Figure 1. Halo nevi and vitiligo patches on the
anterior trunk.

Figure 2. Vitiligo patches on the posterior
trunk and associated leukotrichia.

Figure 3. Wood’s lamp enhancement of
depigmented lesions.

Course
• Labs were unremarkable except for a mild anemia and TSH
was normal.
• The patient was started on betamethasone dipropionate
0.05% ointment BID and Gingko biloba (60 mg BID) and
alpha lipoic acid (100 mg QD) capsules.
• He was referred to ophthalmology, who performed an
unremarkable ocular exam to rule out ocular sites of
melanoma.
• At his 4-month follow-up, he stated that he stopped using
betamethasone dipropionate 0.05% ointment when it ran
out but continued gingko biloba and alpha lipoic acid daily.
• He does not note any new lesions but also no improvement
in current depigmented spots.
• Due to insurance issues, the patient was unable to initiate
narrowband ultraviolet light therapy or start topical
tacrolimus ointment.

Discussion
• Although usually benign, HN have two important
associations:
vitiligo
and
melanoma-associated
leukoderma. Melanoma-associated leukoderma was ruled
out in our patient with total body skin exam and referral to
ophthalmology for ocular exam.
• While the exact pathophysiology of HN is poorly
understood, melanocytes are absent under histopathology,
suggesting a link to vitiligo. Overall, HN is a clinical
indicator of a cellular immune response targeting abnormal
4
melanocytes. This may indirectly relate to the mechanisms
implicated in vitiligo. Specifically, nonsegmental vitiligo,
such as in our patient, is more often associated with an
autoimmune background than segmental vitiligo.1
• Notably, our patient also had (premature hair greying)
PHG, which refers to focal graying of scalp hair. It is
known that lesional leukotrichia and family history of PHG
may be seen in patients with non-segmental HN-associated
vitiligo.1,5 However, reports of focal PHG of the scalp hair
occurring concurrently in a patient with presentation of
HN-associated vitiligo are lacking. Nevertheless, PHG is a
very unusual finding in a patient with HN-associated
vitiligo. In patients with multiple HN, PHG may represent a
robust immune response that warrants search for melanoma
as a possible trigger due to its association with multiple
new HN.5
• Our patient’s acute clinical presentation of HN, nonsegmental vitiligo, and PHG represents a rare triad. While
PHG may be related to an autoimmune/autoinflammatory
process, it is not thought of as such. Thus, further research
of the pathophysiology and clinical course of these findings
in the context of HN-associated nonsegmental vitiligo may
guide management and provide insights into disease
prognosis.
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